Peritoneal cancer treatment

We found 36 clinics & 57 doctors for Peritoneal cancer Worldwide. AiroMedical ranks among 437 hospitals based on qualification, experience, success rate, and awards.

The spread of malignant cells along the inner lining of the abdominal cavity is called peritoneal cancer. The process can be primary or metastatic from the ovaries, uterus, intestines, and bladder. The modern treatment combines surgery (cytoreductive surgery) with advanced local heated chemotherapy (HIPEC) or aerosolized chemotherapy within the abdominal cavity.

Peritoneal cancer is a rare tumour that develops on the inner abdominal wall. Because the ovaries and peritoneum surface cells are similar and their symptoms, as a rule, are identical, the two cancers are often confused. Depending on the place of beginning a lump, the peritoneal tumour is divided into:

  • Primary peritoneal cancer (mesothelioma) occurs when the oncology process begins directly in the peritoneum and then can move to other organs.
  • Secondary peritoneal cancer (carcinomatosis) occurs when cancer of other organs (ovaries, stomach, intestines) begins, and their metastases lead to peritoneal cancer.

The prevalence of peritoneal cancer is 6.78 per 1,000,000 people each year. The most malignant type of the disease (carcinoma) accounts for 10% of all pelvic cancers. In addition, about 10% of women with ovarian and uterine cancer will develop peritoneal cancer.

The disease from the beginning might cause warning signs. However, often the symptoms are general and may be similar to those of ovarian cancer. For example, people with peritoneal malignancy may experience these symptoms: weakness, loss of appetite, abdominal or pelvic pain, constipation or diarrhoea, bloating, early satiety, and frequent or rapid urination.

A multidisciplinary team of doctors handles the treatment of peritoneal cancer. The therapy tactics depend on the type, stage and extension. Several surgical interventions exist to target and remove the affected tissue, organs and lymph nodes. Modern surgical oncology teams can offer HIPEC (hyperthermic intraperitoneal chemotherapy) combined with CRS (cytoreductive surgery) or more innovative options like PIPAC (pressurized intraperitoneal aerosol chemotherapy) and transarterial chemoperfusion.

Systemic chemotherapy uses anti-cancer drugs to stop peritoneal cancer spread and reduce the oncological process. Systemic chemotherpay is usually combined as a neoadjuvant (before the surgery) or adjuvant (after the surgery) method. Finally, targeted and immunotherapy are prescribed as adjuncts to the primary treatment or reduce the risk of relapse.

The survival rate varies depending on the type, grade and spread of the malignancy. Usually, the overall prognosis is poor. The 5-year survivorship is 26%, which makes it challenging to treat. Unfortunately, peritoneal cancer is often diagnosed at stages likely to spread throughout the body, creating a high risk of recurrence after the surgery.

Show more

6 countries and 20 cities for Peritoneal cancer